# Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

Source: https://onco.cc/trials/nct06044623/  
OnCo record `nct06044623` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Geriatric assessment in Breast cancer, run by Region Örebro County, now recruiting.

## Summary

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients is a phase 3 interventional study registered as NCT06044623 by Region Örebro County, with 495 participants planned, started 2024-04-01 and due to reach its primary completion in 2028-10-31. Interventions recorded: CDK 4/6 inhibitors, Endocrine therapy. Conditions recorded: Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity, Older Patients.

Linked to the technology Geriatric assessment because the registry's title names it ("geriatric assessment") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06044623
- Phase: 3
- Setting: Implementing Geriatric Assessment for Dose Optimization of CDK 4/6-inhibitors in Older Breast Cancer Patients - a Pragmatic Randomized-controlled Trial (IMPORTANT Trial)
- Sponsor: Region Örebro County
- Enrolled: 495

## Sources

- ClinicalTrials.gov NCT06044623: https://clinicaltrials.gov/study/NCT06044623

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [Geriatric assessment](https://onco.cc/technologies/geriatric-assessment/)

---
JSON: https://onco.cc/api/v1/entities/nct06044623.json